Fulgent Genetics Reports Q1 2025 Earnings Results

Fulgent Genetics reported a strong start to 2025 with a 16% year-over-year growth in core revenue for Q1, reaching $73.5 million, and maintained its full-year revenue guidance despite posting a GAAP loss. The company ended the quarter with substantial cash reserves and repurchased over half a million shares, reflecting confidence from management, including a major insider purchase by CFO Paul Kim. However, analysts remain neutral on the stock due to ongoing financial challenges such as declining profitability and negative momentum, with the share price experiencing notable volatility over the past year. Technical analysis indicates limited momentum, and the stock has traded between a 52-week low of $14.57 and a high of $25.11. Fulgent continues to focus on expanding its clinical diagnostics and precision medicine businesses, supported by insider ownership and new strategic partnerships. Overall, while recent financials show promise, market sentiment remains cautious given the company's ongoing profitability concerns and share price fluctuations.